Diomed patent case proceeds to trial: U.S. District Court for Massachusetts finds that Diomed's patent on endovascular laser treatment for varicose veins is valid and enforceable. In a sealed order, dated Aug. 30, the Massachusetts court grants Diomed's motion for summary judgment, rejecting the patent invalidity claims by AngioDynamics and Vascular Solutions. The ruling relates to Diomed's patent on its EndoVenous Laser Treatment, which it acquired in 2003. The firm brought charges in 2004 against AngioDynamics (VenaCure) and Vascular Solutions (Vari-Lase) seeking injunctive relief and damages for alleged infringement. With the validity issue decided, Diomed is cleared to proceed to trial, expected to commence in 2007. The defendants hold that the decision is not a determination of whether patent infringement has actually occurred...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.
While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.
